CHO-CXCR7 is a recombinant clonal stable CHO cell line expressing full length human C-X-C chemokine receptor type 7 (CXCR7). Surface expression of CXCR7 was confirmed by flow cytometry using specific antibodies. Detailed information and characterisation can be found in the Product Sheet.
Target Aliases
ACKR3, GPR159, RDC1
Target Expression Level(s) Available
Low (receptor density not analyzed by Quantibrite)
Medium-high (receptor density not analyzed by Quantibrite)
Cell Background
CHO-K1 (Chinese Hamster Ovary), epithelial-like cells, adherent
INS-SF-1007-L: can not be adapted to suspension culture
INS-SF1007-MH: can be adapted to suspension culture
Buying and Ordering the Cells
For non-profit organizations, cells are available for perpetual academic research under the Limited Research Use License.
For-profit entities can purchase cells for perpetual commercial use under the Limited Commercial Use License.
To request a quote, please email us at or use the contact form provided below.
We are already registered on several digital order processing platforms, if you would like to add us as a registered supplier, please contact us at and we are happy to help.
Supplied as
Each license includes 1 vial of >2Mio viable cells. Additional or replacement vials can be purchased for a fee of 450€.
Target Info
Background
CXCR7, also known as ACKR3, is an atypical chemokine receptor (interceptor) with a distinct role in modulating immune responses and tumor biology.
Unlike classical GPCRs, CXCR7 does not signal through G proteins; instead, it modulates cell responses by scavenging chemokines, particularly CXCL12 and CXCL11, and forming heterodimers with CXCR4.
CXCR7 overexpression in various cancers, such as breast, lung, and prostate cancers, correlates with increased tumor growth, metastasis, and poor prognosis. CXCR7 enhances tumor progression by altering the tumor microenvironment, promoting angiogenesis, and facilitating cancer cell migration and invasion.
Field of Research
- Cardiovascular diseases
- Autoimmunity and inflammation
- Oncology
Therapeutics and Binding Partners
There is currently no approved therapeutic that specifically targets the CXCR7 protein. There are also no late stage clinical trials in progress.
Selected Therapeutics
- ACT-1004-1239 (Phase-I)
Selected Binding Partners
- CXCL12 (also know as SDF-1α)
- CXCL11 (also known as I-TAC)
Product Details
Stable recombinant CHO cells at low and high confluency, cultured in CHO Growth Medium A (INS-ME-1039) as a 2D monolayer.
Expression of CXCR7 in CHO-CXCR7 cells (INS-SF-1007) analyzed by Flow Cytometry.
Primary antibody: APC anti-human CXCR7 Antibody (Biolegend, Cat.No.: 391405) was used at 1:100 dilution as per manufacturer’s recommendations.
Flow Cytometry was performed according to the protocol provided under the „Protocols“ tab.
Quantification: Receptor density was not analyzed by Quantibrite.
Controls: CHO control – Parental Landing Pad cells, stably transfected with an empty vector.
We recommend the following reagents for the cell culture of this cell line:
Growth Medium:
- For Low expressing cell line (INS-SF-1007-L): CHO Growth Medium A (INS-ME-1039)
- For Medium-high expressing cell line (INS-SF-1007-MH): CHO Growth Medium B (INS-ME-1040)
Freezing Medium:
- For Low expressing cell line (INS-SF-1007-L): CHO Freezing Medium A (INS-SU-1023)
- For For Medium-high expressing cell line (INS-SF-1007-MH): CHO Freezing Medium B (INS-SU-1024)
Coating: not required
Please note that compositions for the above listed reagents are available on their respective product sites, as well as in the cell line Product Sheets, should you wish to prepare your own reagents.
Coming Soon!
Stay tuned for comprehensive protocols for this cell line, from routine cell cultures to assay manuals.
Coming Soon!
Coming Soon!
Material:
- PBS/EDTA solution
- 2% FBS/FCS in PBS (FACS Buffer)
- primary antibody (concentration is indicated under „Target expression“ tab)
Protocol:
Wash Protocol: Add FACS Buffer, resuspend cells gently, then centrifuge at 300×g for 5min.
- Prepare detection reagents in FACS buffer using the concentrations indicated under Materials.
- Aspirate medium from cells.
- Add PBS/EDTA solution to the cells and incubate at room temperature or 37°C for 5-10min, or until the cells detach.
- Wash cells 1×.
- Add primary antibody in FACS buffer, resuspend cells gently.
- Incubate at ambient temperature for 20-30min.
- Wash cells 2×.
- Resuspend in 100-200µl FACS Buffer.
- Analyse cells using a flow cytometer.
For a more detailed protocol, please see the BD Biosciences Quantibrite instructions.
Important: All instrument settings for fluorescence and compensation must be the same as the cellular assay settings.
- Reconstitute the BD Quantibrite beads using 0.5 mL of buffer, such as phosphate buffered saline (PBS) with sodium azide plus 0.5% bovine serum albumin (BSA), and vortex.
- Measure fluorescence of singlet beads using a flow cytometer and extract the geometric means of all four fluorescence peaks.
- Measure cells using the same instrument settings.
- Use the lot-specific values for the PE molecules per bead and linear regression to calculate the PE molecules per cell (approximation of target molecules per cell)
- For an even more meaningful result, contact the antibody provider for information on the number of fluorescent molecules per antibody.
Related Products
Product FAQ
Yes, for selected targets, we provide cell lines that exhibit varying expression levels. Detailed information regarding the availability of different expression levels can be found in both the ‚Product Summary‘ and ‚Product Details‘ sections.
Cell lines with available expression level variations are denoted by an abbreviation following the catalog number. For instance, ‚INS-SF-1020-MH‘ denotes a cell line with medium-high expression levels, whereas ‚INS-SF-1020-L‘ indicates a cell line with low expression of the same target.
Should you require a specific expression level not readily available in our standard product range, we also offer custom cell line generation services utilizing our advanced Landing Pad technology.
For several targets, we already have ready-to-use cell lines available in both CHO and HEK293 backgrounds. Please refer to Related Products section, or have a look at our product catalog to see if your target and the desired cell line are listed.
For any other specific cell line background such as A549, MIA PaCa-2, or any other cell line, we currently do not offer pre-established cell lines. However, we are pleased to provide a custom cell line development service. Through this service, we can express your target in virtually any cell background utilizing random integration techniques, tailored to meet your research needs.
For the best performance of this cell line, we advise using our Medium and Coating Solutions specified in the product sheet. These have been specially optimized for these cells.
For our off-the-shelf stable recombinant cell line, we also disclose the Medium composition in the Product Sheet so you can make your ownMedium.
All our stable recombinant cell lines are provided as adherent cultures, if not indicated otherwise in the Product Sheet.
Some of our CHO cell lines can be easily adapted to suspension culture. If a particular cell line can be cultured in suspension is indicated in the product summary section at the top of the page under Cell Background, as well as in the Product Sheet, where you will also find detailed protocols for suspension culture.
Our stable recombinant cell lines are generated using our proprietary Landing Pad Technology, in which we use targeted integration at pre-validated genomic locations to express the target. You can find more details on our Landing Pad technologies under our Landing Pad Services.
After cell line generation, target expression levels were validated by Flow Cytometry using the reagents and protocols indicated in the section Product Details or in the Product Sheet.
This cell line is BSL 1 according to German legislation. However, persons working with such cell lines and their employers are required to familiarize themselves with the national regulations and safety precautions, as they may differ. Our provided biosafety classification does not provide any exemption from this responsibility.
Literature and Reference
We love to hear about your research! Please let us know if you have published using our cells.